3 results
To demonstrate superiority of the NEURO TRONIC SC-KAFO in stance control securing while walking under challenging conditions compared to the E-MAG Active SC-KAFO; and to demonstrate superiority of the NEURO TRONIC SC-KAFO on walking energy cost,…
To prospectively collect and assess global safety and efficacy data on the IN.PACT Admiral* Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease of the superficial femoral and/or popliteal arteries in *real world* patient population.
The primary aim is to investigate the effect of neuromodulation (via UCon) on the symptoms of patients with PGAD. The hypothesis we want to test is whether neuromodulation of the DGN reduces the severity of symptoms of PGAD.